000			03076cam a2200349 a 4500
003			EG-GiCUC
005			20250223031806.0
008			170916s2016 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.11.07.Ph.D.2016.Sa.A
100	0		_aSaid Fathy Hotar
245	1	0	_aAssessment of CMV-specific CD8⁺T lymphocytes after stem cell transplantation / _cSaid F. Hotar ; Supervised Ahmed Ali Shams Eldin , Nermeen Ahmed Eldesoukey , Neveen M. Baha Eldin Fouad
246	1	5	_aقياس الخلايا الليمفاوية من النوع الايجابى ل سى دى 8 و المضاده للفيروس المضخم للخلايا (سى ام {uئآ٦آ}) فى مرضى زراعة الخلايا الجزعية
260			_aCairo : _bSaid Fathy Hotar , _c2016
300			_a155 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
520			_aHematopoietic stem cell transplant (SCT) is one of the most important lines of treatment of hematological and non hematological diseases which may be allogeneic, autologous using bone marrow, peripheral blood or placental blood. Human cytomegalovirus (CMV) infects 60-90% of individuals worldwide and remains latent in the infected host, CMV infection is an important cause of morbidity and mortality in immunosuppressed hematopoietic stem cell transplant (SCT) recipients. CMV-specific CD8+cytotoxic T lymphocytes play a critical role in suppressing CMV reactivation. The antigen-specific T lymphocytes may be enumerated without the requirement of in vitro stimulation by flowcytometry using major histocompatibility complex (MHC) tetramers. MHC tetramers are complexes between HLA class I or class II molecules and specific antigenic peptides conjugated to fluorochromes, These complexes bind to a distinct set of T-cell receptors on a subset of CD8-T cells. The iTAg MHC Tetramers show a greatly diminished binding to the general population of CD8 cells allowing for rapid and sensitive quantitative measurement of an individual patient's T cell response to a specific virus, So evaluation of MHC Tetramer measurement of this response and correlating it with recovery against CMV is expected to be of great help of planning antiviral therapy regimen. Post transplantation immunodeficiency needs immunotherapy or immunization strategies to control the recovery of T-cell responses against viral antigens, as well as those used to manage graft-versus-host disease and infection following transplantation
530			_aIssued also as CD
653		4	_aBone marrow transplantation
653		4	_aCMV
653		4	_aFlowcytometry
700	0		_aAhmed Ali Shams Eldin , _eSupervisor
700	0		_aNermeen Ahmed Eldesoukey , _eSupervisor
700	0		_aNeveen Mohamed Baha Eldin Fouad , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c62316 _d62316